Background-When β-blockers produce reverse-remodeling in idiopathic dilated cardiomyopathy, they partially reverse changes in fetal-adult/contractile protein, natriuretic peptide, SR-Ca 2+ -ATPase gene program constituents. The objective of the current study was to further test the hypothesis that reverse-remodeling is associated with favorable changes in myocardial gene expression by measuring additional contractile, signaling, and metabolic genes that exhibit a fetal/adult expression predominance, are thyroid hormone-responsive, and are regulated by β 1 -adrenergic receptor signaling. A secondary objective was to identify which of these putative regulatory networks is most closely associated with observed changes. Methods and Results-Forty-seven patients with idiopathic dilated cardiomyopathy (left ventricular ejection fraction, 0.24±0.09) were randomized to the adrenergic-receptor blockers metoprolol (β 1-selective), metoprolol+doxazosin (β 1 /α 1 ), or carvedilol (β 1 /β 2 /α 1 ). Serial radionuclide ventriculography and endomyocardial biopsies were performed at baseline, 3, and 12 months. Expression of 50 mRNA gene products was measured by quantitative polymerase chain reaction. Thirty-one patients achieved left ventricular ejection fraction reverse-remodeling response defined as improvement by ≥0.08 at 12 months or by ≥0.05 at 3 months (Δ left ventricular ejection fraction, 0.21±0.10). Changes in gene expression in responders versus nonresponders were decreases in NPPA and NPPB and increases in MYH6, ATP2A2, PLN, RYR2, ADRA1A, ADRB1, MYL3, PDFKM, PDHX, and CPT1B. All except PDHX involved increase in adult or decrease in fetal cardiac genes, but 100% were concordant with changes predicted by inhibition of β 1 -adrenergic signaling. Conclusions-In addition to known gene expression changes, additional calcium-handling, sarcomeric, adrenergic signaling, and metabolic genes were associated with reverse-remodeling. The pattern suggests a fetal-adult paradigm but may be because of reversal of gene expression controlled by a β 1 -adrenergic receptor gene network.
I diopathic dilated cardiomyopathy (IDC) is a common type of nonischemic dilated cardiomyopathy for which no cause is readily apparent. 1 The main phenotypic feature of IDC and other types of heart failure (HF) with reduced ejection fraction (EF) is ventricular chamber remodeling characterized by contractile dysfunction and eccentric pathological hypertrophy. These processes are commonly detected and quantified by measurement of left ventricular (LV) volumes and the derived EF, which relates a measure of systolic function (stroke volume) to the degree of eccentric hypertrophy (end-diastolic volume [EDV] ). IDC in humans is associated with myocardial gene expression changes affecting contractile function and hypertrophy. 2, 3 Among these are upregulation in mRNA and protein abundances of β-myosin heavy chain (MYH7) and atrial natriuretic peptide (NPPA) with downregulation of α-myosin heavy chain (MYH6) and sarcoplasmic reticulum calcium-ATPase 2 (ATP2A2), a pattern also observed during fetal cardiac development. 2, 3 Reversal of these pathological changes is associated with ventricular reverse-remodeling in response to both β 1 -selective and nonselective β-adrenergic receptor (AR) antagonists, 3 suggesting that reversal of abnormalities in gene expression driven by chronic β 1 -AR stimulation may mediate salutary effects of β-blockers in IDC and potentially other forms of HF with reduced EF.
Relationships between β 1 -adrenergic signaling, changes in contractile-and hypertrophy-related gene expression, progression of LV dysfunction and reversal of molecular and structural remodeling by blockade of β 1 -ARs are incompletely understood. Analysis of gene expression in septal endomyocardial biopsies obtained by right heart catheterization in the presence of β-blocker-associated reverse-remodeling constitutes a human model of gene function associated with changes in ventricular myocardial phenotype. We previously reported effects of β-blockers on human myocardial remodeling and gene expression using an early generation method of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) that could measure only a small number of mRNAs. 3 That work was necessarily narrowly focused, and other gene categories potentially important in therapeutic response to β-blockers were not investigated. New tools using small amounts of RNA including improvements in qPCR methods and microarrays 4 have greatly increased the potential yield of investigations, where serial measurements of gene expression are coupled to therapeutic modulation of organ-specific phenotype.
We present here the β-blocker Effect On Remodeling and Gene Expression Trial (BORG, NCT01798992), which combined gene expression analysis of endomyocardial biopsy specimens with phenotypic measurements of LV structure and function. BORG is a next-generation longitudinal study of myocardial gene expression and reverse-remodeling in patients with IDC treated with 3 different regimens of AR antagonists that have in common blockade of β 1 -AR. BORG investigated relationships between myocardial gene expression and cardiac phenotypic change, the contribution of α 1 -and β 2 -AR blockade, and changes in expression of gene families beyond the current cardiac fetal/adult gene program paradigm. The primary hypothesis was that ventricular reverse-remodeling associated with β 1 -AR blockade is driven by changes in contractile-or hypertrophy-modifying myocardial gene expression that either precedes or occurs contemporaneously with reverseremodeling. Specifically, we hypothesized that candidate genes involved in AR signaling, renin-angiotensin and endothelin systems, cytokine signaling, muscle contraction, calcium handling, metabolism, and gene transcription would exhibit unique changes comprising a therapeutic molecular phenotype associated with ventricular reverse-remodeling and that observed changes would fit into a fetal/adult, 3 β 1 -AR-driven, 5, 6 or thyroid hormone-responsive pattern. 7 To test this hypothesis, we quantified candidate gene mRNA expression using qPCR and microarray analysis in the context of changes in LV structure and function in response to β-blocker therapy.
Methods
The primary outcome was a positive LVEF reverse-remodeling response defined as an improvement ≥8 EF units at 12 months or if not available, an improvement ≥5 EF units at 3 months (last-observation-carried-forward or LOCF). The LVEF definition of β-blocker response was based on previous observations of improved LVEF with β-blockers compared with placebo. 3, 8 The 3-month LVEF response cutoff was based on previously demonstrated favorable changes in fetal gene program components associated with an improvement ≥5 EF units after a longer treatment interval of 6 months. 3 The 12-month cutoff was defined based on a blinded, prospective analysis of mean LVEF improvement at 12 months among those with improvement ≥5 EF units at 3 months. Nonresponse was defined as not meeting the positive response criteria or the occurrence of heart transplant, LV assist device placement or death.
Expression of 50 candidate mRNA gene products and 2 reference genes ( Table 1) was quantified by RT-qPCR. Gene expression changes associated with pathological LV remodeling were identified by comparing differences in gene expression between IDC and nonfailing control patients. Changes associated with reverse-remodeling were identified by comparing gene expression at LOCF with baseline gene expression in patients with a positive LVEF response (responders) to patients with LVEF nonresponse (nonresponders). 3 Analysis of differences in gene expression between the 3 AR-blocking groups was a secondary objective and will be reported separately.
Study Design
This study was conducted between 2000 and 2008 at the Universities of Colorado and Utah according to the Declaration of Helsinki and included a Data Safety Monitoring Board. The study was approved by institutional review boards at both sites, and all subjects gave written informed consent. Patients were eligible for enrollment if they had IDC and New York Heart Association class II-IV symptoms with an LVEF ≤40%, were ≥18 years old, had angiographically confirmed unobstructed coronary arteries, and were receiving conventional medical HF therapy except β-blockers for ≥3 weeks before enrollment. Exclusion criteria included HF because of valvular disease; thyroid disease; obstructive or hypertrophic cardiomyopathy; pericardial disease; amyloidosis; myocarditis; heart transplant candidacy; decompensated HF; ongoing treatment with nondihydropyridine calcium channel blockers, theophylline, tricyclic antidepressants, monoamine oxidase inhibitors, β-agonists, β-blockers, or inotropes; life expectancy<2 years; active substance abuse; recently fired implantable cardiac defibrillator; bradycardia; uncontrolled insulindependent diabetes mellitus; high-degree atrioventricular block; or history of noncompliance.
Patients were randomized in an unblinded fashion to commercially available formulations of carvedilol (COREG), metoprolol succinate (TOPROL-XL), or metoprolol succinate+doxazosin mesylate (CARDURA). The starting dose of carvedilol, a β 1 /β 2 /α 1 -AR blocking agent, was 3.125 mg twice daily with targets of 25 mg (patients <85 kg) or 50 mg (patients ≥85 kg) twice daily. 9 The starting dose of metoprolol succinate, a β 1 -AR selective blocking agent, was 12.5 mg daily with a target of 200 mg daily. 10 Doxazosin mesylate, an α 1 -AR selective blocking agent, was started at 1 mg daily with a target of 8 mg daily. 11 All medications were up-titrated weekly until target doses were met or limiting side effects developed.
Endomyocardial biopsy may be considered clinically in patients with IDC to rule out causes of myocardial disease that might affect prognosis or therapy. 1, 12 Patients underwent right heart catheterization via right internal jugular vein with right ventricular (RV) endomyocardial biopsy from the distal septum at baseline, 3, and 12 months where the 3-and 12-month biopsies were used for RNA extraction for research purposes only. Biopsies were performed on all patients with IDC by personnel experienced in performing RV biopsies in nontransplant patients under echocardiographic guidance, and 15 to 25 mg of tissue was removed. Biopsies were also taken from 5 potential nonfailing control patients with LVEF≥45% who were studied for other indications to rule out myocardial disease. Histological analysis of baseline biopsies reported hypertrophy in 71%, increased interstitial fibrosis in 39%, and evidence of inflammation/mononuclear infiltrate in 11%. One potential control was excluded because of giant cell myocarditis on histological examination, whereas the other 4 potential control biopsies had no evidence of hypertrophy, fibrosis, or inflammation and were used in the study. LVEF was measured within days of each biopsy by radionuclide ventriculography (Data Supplement). RNA was extracted from all patients with IDC and nonfailing control biopsy samples, cDNA was synthesized, and 
Statistical Analysis
Clinical and gene expression data were imported into the R statistical package (version 3.0.2; R Foundation for Statistical Computing, Vienna, Austria). Patients were aggregated by LVEF response status, and clinical differences between responder groups were assessed using Fisher exact and Welch t test for categorical and continuous variables. Marked skew was noted in some C t distributions, and outliers were identified and removed using a median absolute deviation threshold >3.5, congruous with an α of 0.05 using parametric statistical analysis (276 of 13 100 values, 2.1%). 13 If a subject's baseline sample was excluded or unavailable, follow-up samples were excluded. Changes in gene expression from baseline to LOCF (month 12 values or if not available, month 3 values) and with treatment were approximated using the ΔΔC t method with GAPDH as the reference gene. 14 Significance of changes in gene expression from baseline was determined using the nonparametric paired Wilcoxon signed-rank test in responders and nonresponders separately. Fold changes and aggregate statistics were calculated using normalized C t differences (2 -ΔΔCt ). All tests were 2 tailed, and a P<0.05 was considered significant. Comparisons were repeated using the arithmetic mean of GAPDH and 18S rRNA expression to determine the effect of normalization strategy on results. Microarray data were normalized by log-scale robust multiarray analysis. 15 Cognate microarray data corresponding to the 50 RT-qPCR genes were also analyzed, and changes in expression from baseline were compared between responders and nonresponders using the Wilcoxon rank-sum test. A P<0.05 by microarray was considered confirmatory of a significant RT-qPCR finding.
Changes in gene expression were compared between responders and

Results
Outcomes of Enrolled Patients
A total of 63 patients with IDC met screening criteria and gave written informed consent ( Figure 1 ). Of these, 6 subjects withdrew before baseline studies for personal or administrative reasons, 2 had normalization of a reduced LVEF obtained on a previous examination, and central venous access could not be obtained in 1 leaving 54 subjects who underwent baseline studies. In 2 subjects, radionuclide ventriculography revealed their LVEFs had normalized since screening, and their biopsy samples were analyzed as nonfailing controls. Of the randomized 52 subjects, 47 returned for 3-month studies and 40 returned for 12-month studies. Therefore, 47 patients had ≥1 follow-up biopsy and LVEF measurement after baseline and were included in all subsequent analyses. There were no complications from endomyocardial biopsy or right heart catheterization.
In total, 39 of 47 (83.0%) patients achieved target β-blocker dose including 16 of 16 carvedilol patients(mean daily dose, 75±24 mg), 13 of 17 (76.5%) metoprolol patients (mean daily dose, 163±60 mg), and 10 of 14 (71.4%) metoprolol+doxazosin patients (mean daily metoprolol dose, 171±51 mg). Target doxazosin dose was reached in 10 of 14 patients (71.4%, mean daily dose, 6±3 mg). Of the 5 patients not analyzed, 1 subject had inadequate tissue for RT-qPCR at the only follow-up visit, 2 relocated, and 2 were withdrawn for administrative reasons. One patient in the carvedilol arm died suddenly 10 months after randomization, and 1 patient underwent ventricular assist device placement after 16 months. There were no heart transplants during the study. A total of 8 patients (4 responders and 4 nonresponders) had 3 to 12 months LOCF imputation.
Baseline characteristics of IDC versus nonfailing control subjects and LVEF responders versus nonresponders are shown in Tables 2 and 3 units; P=0. 14) , the respective changes were not significantly different (P=0.27). Systolic blood pressure and cardiac index also increased significantly in responders only compared with baseline, but differences between responder groups were not significant.
Gene Expression Changes
Expression of the 50 candidate genes normalized to GAPDH at baseline in patients with IDC is compared with control patients in Figure 2 . Compared with controls, 11 of 50 (22.0%) genes were differentially expressed in patients with IDC. ADRB1, ATP2A2, MYH6, and ACTC1 were expressed at significantly lower levels in patients with IDC, whereas MYL2, HK2, PDHX, CTF1, TNNI3, NPPA, and NPPB were expressed at significantly higher levels. The ACTC1/ACTA1 ratio was significantly lower in patients with IDC than in nonfailing controls (0.77±0.09 versus 1.76±0.5; P=0.024), whereas MYH6/MYH7 (P=0.06) and ATP2A2/PLN (P=0.28) ratios were not significantly different.
Fold changes in myocardial gene expression from baseline by responder status are shown in Figure 3 . Expression of 13 of 50 (26.0%) genes (ACTA1, TNNC1, TNNI3, IL6, GNAI2, GNAS, SLC8A1, SLC9A1, MYL2, ACTC1, HK2, CTF1, and CSRP3) decreased significantly and 3 of 50 (6.0%) genes (CANX, PDK4, and Tr-α1) increased more in responders with no differences versus changes in nonresponders. Expression of 11 of 50 (22.0%) genes (ADRB1, ADRB2, ADRA1A, ATP2A2, PLN, RYR2, MYH6, MYL3, CPT1B, PDHX, and PFKM) increased more or decreased less in responders versus nonresponders, whereas expression of 2 (4.0%) genes (NPPA and NPPB) decreased significantly in responders versus nonresponders. MYH6/MYH7 (1.96±0.32 versus 0.78±0.07; P<0.001) and ACTC1/ACTA1 (1.91±0.32 versus 0.87±0.11; P<0.05) ratios also increased in responders, whereas change in the ATP2A2/PLN ratio was not significantly different (P=0.37) between responder groups. When 3-month (n=47) and 12-month (n=39) samples were considered separately, PFKM and RYR2 were significantly different in responders versus nonresponders at 3 months only; ADRB1, ADRB2, ATP2A2, PLN, MYH6, and MYL2 were significantly different at 12 months only; and NPPA, NPPB, and MYL3 were significantly different at both time points. No genes were significant at either 3 or 12 months that were not significant in LOCF analysis. Neither GAPDH nor 18S rRNA changed significantly in analysis of nonnormalized Ct data (P>0.4 and P>0.3, respectively). However, the expression of 18S rRNA decreased significantly relative to GAPDH on all 4 qPCR plates in responders (fold change, 0.47-0.59; P<0.01) but not in nonresponders (P>0.14). All genes with significant differences between responders and nonresponders in serial gene expression normalized to GAPDH alone remained significant when normalized to the composite of GAPDH and 18s rRNA. The ratio of MYH6/MYH7 was also significantly higher in responders versus nonresponders normalized to the composite of GAPDH and 18S rRNA (2.00±0.30 versus 0.9±0.11; P<0.01), whereas the ACTC1/ACTA1 ratio was higher in responders but not statistically significant (1.98±0.51 versus 1.00±0.20; P=0. 10) .
Genes that demonstrated differential expression changes between responders and nonresponders by RT-qPCR were also tested by microarray. Of these, 8 of 13 genes (MYH6, MYL3, PLN, RYR2, NPPA, NPPB, and PFKM) were also significantly differentially expressed on microarray with the same directionality (P<0.05). Increases in MYH6/MYH7 and ACTC1/ACTA1 ratios were also significant (P<0.01) by microarray in responders than in nonresponders. Changes in ADRB1, ATP2A2, ADRA1A, CPT1B, and PDHX had the same directionality by microarray analysis and RT-qPCR, but differences between responder groups were not significant.
Discussion
These data provide the most comprehensive longitudinal analysis reported to date of myocardial gene expression associated with reverse-remodeling in patients with dilated cardiomyopathy. Because the intraventricular septum is shared between the ventricles and forms interdependent anatomic relationships with both the LV and the RV free walls, 16 molecular changes relative to LV structure and function will be detected by septal endomyocardial biopsy. 3 In the current study, responders exhibited a robust improvement of 21±10 EF units, whereas changes in RVEF and hemodynamic parameters were not significantly different between responders and nonresponders.
Therefore, it is likely that the observed changes in gene expression selectively present in responders reflect intrinsic biological changes in the LV chamber as opposed to changes in RV function, heart rate, or LV loading conditions. In addition, the study design comparing responders to nonresponders who were given equivalent β 1 -AR blocking target doses 3 at similar levels in responders and nonresponders minimizes the degree of β 1 -blockade as a mechanism for the observed differences. The present study provides insight into gene expression changes associated with LV reverse-remodeling with improvement in systolic function or regression of pathological hypertrophy, as well as myocardial response to β-blocker therapy irrespective of reverse-remodeling.
Gene Expression Changes in β-Blocker Treatment Associated With Reverse-Remodeling
The observed changes indicate increased expression in genes affecting contractile function, calcium handling, energy substrate use, and adrenergic signaling plus decreases in Figure 2 . A, Baseline gene expression normalized to GAPDH: adrenergic signaling and contractile/cytoskeleton proteins in idiopathic dilated cardiomyopathy (IDC; n=47) vs controls (n=4). ADRB1, MYH6, and ACTC1 expressed at lower levels in IDC than controls, whereas MYH2 and TNNI3 were expressed at higher levels in patients with IDC. B, Baseline gene expression normalized to GAPDH: calciumhandling and cytokine pathways in IDC (n=47) vs controls (n=4). ATP2A2 was expressed at lower levels in IDC than in controls, whereas CTF1 was expressed at higher levels in patients with IDC. C, Baseline gene expression normalized to GAPDH: metabolic pathways and counter-regulatory, transcription factors, and other genes in patients with IDC (n=47) vs controls (n=4). HK2, PDHX, NPPA, and NPPB were expressed at higher levels in patients with IDC.
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natriuretic peptides, which are biomarkers of failing or hypertrophied myocardium. We reported previously that when β-blocking agents produce reverse-remodeling in IDC, they affect a partial reversal of HF-associated changes in expression of genes encoding β 1 -AR (ADRB1), 17 contractile proteins (MYH6 and MYH6/MYH7 ratio), 3 natriuretic peptides (NPPA), 3 and sarcoplasmic reticulum calcium-ATPase 2 (ATP2A2). 3 The results of BORG confirm those findings and extend the observations to increases in expression of additional contractile (ACTC1/ACTA1 ratio, MYL3) and calciumhandling genes (PLN, RYR2) . We also report changes in additional categories of genes associated with reverse-remodeling including the metabolic pathway genes CPT1B and PFKM and the α 1 -AR gene ADRA1A. The use of both fatty acids and glucose as energy sources is decreased in advanced HF, 18 limiting ATP synthesis. Coordinated upregulation of both PFKM and CPT1B has been demonstrated in response to β-blockade, suggesting a return to an adult metabolic gene expression pattern. 19 If accompanied by cognate changes in protein abundance, increased CPT1B should increase fatty acid metabolism, 20 whereas increased PFKM should enhance glucose metabolism. Therefore, upregulation of both free fatty acid and glucose metabolism occurs to achieve higher energy production as LV function improves.
If mRNA abundance changes observed exclusively in responders were translated to protein expression and activity, LV contractile function would be expected to increase because of the improved MYH6/MYH7 ratio and increased expression of MYH6, 21 MYL3, 22 ATP2A2, 23 RYR2, 24 ADRA1A, 25 and ADRB1. 26 In addition, decreases in MYH7/MYH6 27 and ACTA1/ACTC1 28 ratios and reduction in 18S rRNA 29 should be antihypertrophic. Upregulation in unphosphorylated PLN might be negatively inotropic, 30 but increased ADRB1 expression would increase phosphorylated PLN potentially offsetting C Figure 2 . Continued the impact of higher PLN expression. 31 Decreases in NPPA and NPPB might be expected to be hypertrophic, 32 but a previous study also observed that NPPA decreased in both responders and nonresponders, presumably as intracardiac filling pressures fell, 3 and circulating B-type natriuretic peptide has been observed to decrease in association with reverse-remodeling. 33 These data suggest that β 1 -AR blockade, common to all treatment arms, may affect reverse-remodeling by increasing expression of contractile, calcium-handling/calcium-regulating, AR, and metabolic proteins that either improve LV contractile function or participate in its metabolic support.
Of 11 genes that exhibited altered baseline expression in IDC compared with nonfailing controls, 5 (ADRB1, MYH6, ATP2A2, NPPA, and NPPB) were changed in the direction of control values (normalized) only in responders, 2 (TNNI3 and MYL2) normalized in responders without a significant difference versus nonresponders, and 3 (HK2, CTF1, and PDHX) normalized in both responders and nonresponders. These data suggest that β-blocker therapy affects reverse-remodeling by partially normalizing some gene expression changes fundamentally associated with the dilated cardiomyopathy phenotype. Many β-blocker-associated gene expression changes in responders versus nonresponders represent a partial reversal of the cardiac fetal/adult gene program, 3, 34, 35 but they may also be consistent with alternative regulatory mechanisms including inhibition of β 1 -AR signaling 5, 6, 36 or enhanced thyroid hormone receptor (TR-α) activity (Table 5 ). 7 We previously reported changes in TR-α1 and TR-α2 expression in IDC LVs consistent with hypothyroidism at the TR-α level. Furthermore, myocardial expression of TR-α1 is positively correlated with MYH6 expression and negatively correlated with ANP, whereas TR-α2 expression is negatively correlated with MYH6 and positively with ANP expression, suggesting that TR-α expression may influence fetal/adult gene program regulation. In the current study, changes in expression of either TR-α isoform were not different between responder groups although TR-α1 expression increased significantly in responders only, suggesting a TR-α effect was not completely ruled out.
As shown in Table 5 , changes in gene expression associated with LV reverse-remodeling were 100% concordant with changes expected from interruption of chronic β 1 -AR stimulation 5, 36 or cardiac β 1 -AR overexpression, 6 both of which influence the fetal/adult gene program via the Ca 2+ /calmodulin-dependent kinase pathway. 5 Thus, the data are most consistent with a primary effect of a β 1 -blockade of a β 1 -AR gene network in responders overlapping with effects expected for TR-α responsive and fetal/adult developmental gene expression patterns. The expansion of known genes whose expression changes in the setting of β-blocker therapy for IDC may provide additional insight into primary regulatory pathways involved in LV reverse-remodeling. Exploration of these findings may identify factors that determine whether β-blockade produces changes in myocardial gene expression that promote reverse-remodeling in a given individual (ie, why the β 1 -AR network is affected by β 1 -blockade in reverse-remodeling patients only).
Gene Expression Changes Associated With β-Blocker Therapy
Gene expression changes that occur in both responders and nonresponders are the likely result of pharmacological effects of β 1 -AR blockade as opposed to being secondary to ventricular reverse-remodeling. Expression of genes encoding contractile (ACTC1), metabolic (HK2 and PDHX), signaling (CSRP3, GNAI2, GNAS, and SLC9A1), and calcium-handling proteins (SLC8A1) all decreased significantly in both responders and nonresponders. In some cases, these changes represent partial reversal of pathological changes associated with IDC even when not associated with improvement in LVEF. For example, SLC8A1 has been shown to be upregulated in the failing human heart, 37 and inhibition of SLC8A1 has been associated with reduced arrhythmia in experimental models of dilated cardiomyopathy, suggesting potential for improved survival even without reverse-remodeling. 38 
Comparison of Expression Changes in Responders to Previous Studies of Reverse-Remodeling in Human Dilated Cardiomyopathies
Previous studies using cardiac resynchronization therapy [39] [40] [41] or β-blockers 3, 17, [42] [43] [44] to affect reverse-remodeling have reported similar protein or mRNA gene expression changes in ADRB1+ADRB2, 17, 42 ADRB1, 39 MYH6, 3, 40, 41, 43 MYH6/ MYH7, 3, 40, 41, 43 ATP2A2, 3, 41, 44 PLN, 40, 41, 44 NPPA, 3 and NPPB. 41 Responder-specific gene expression changes in RYR2, ADRA1A, MYL3, PDKFM, PDHX, CPT1B, and ACTA1/ ACTC1 have not been previously reported in reverse-remodeling of human dilated cardiomyopathies.
Limitations
Analysis was limited to gene expression changes, which may not be directly translated to changes in functional protein abundance. Because of the quantity of RNA required to perform the mRNA analyses reported in this study, as well as additional microRNA and RNAseq measurements, quantification of protein expression or post-translational modification was not feasible and was not a prespecified aim of the present study. Conclusions about significance of gene expression changes may vary according to assay and normalization standard. GAPDH was selected at the time of trial design based on its widespread use as a reference gene, its midrange expression level, and lack of common regulation, but the use of GAPDH as a normalization standard has subsequently been questioned. 45 Ribosomal 18S rRNA was quantified but is not generally used alone as a reference standard because of its high abundance and the unpredictable balance of rRNA and mRNA in different tissues. 46 We repeated RT-qPCR analysis using a composite of GAPDH and 18S rRNA, and all genes associated with LV response remained significant. We used microarray analysis as an additional confirmatory assay although microarray analysis uses a distinct normalization strategy, and the importance of differences in statistical significance between RT-qPCR and microarray findings is unclear.
Carvedilol is a biased ligand for both β 1 -AR 47 and β 2 -AR 47, 48 , meaning that as it produces receptor blockade it can activate mitogen-activated protein kinase extracellular regulated kinase 1/2 via β-arrestin signaling indepedently of G-protein activation. Metoprolol has also been shown to be a biased ligand for β 1 -ARs, in a pathway that appears to be different from carvedilol. 49 In a previous study, 3 we found absolutely no differences between metoprolol and carvedilol for the 6 mRNAs measure by qPCR. In the current study, there were some differences between the carvedilol and the combined metoprolol groups, 50 but none of them changed the statistical results of the metoprolol groups when the carvedilol data were added. We will be subsequently reporting a complete analysis of gene expression between groups, where the consequences of differences in biased ligand signaling in the carvedilol versus metoprolol groups may become apparent. *Decreased expression of genes expressed at higher levels in embryonic development (fetal genes) or increased expression of genes expressed at higher levels in the adult than in embryonic development (adult genes).
†Directionally opposite regulation from that produced by β 1 -adrenergic receptor stimulation 5, 36 or transgenic cardiac overexpression. 6 ‡Changes in gene expression concordant with thyroid hormone stimulation or thyroid hormone-α 1 expression. 7 April 2015
Conclusions
LV reverse-remodeling in patients with IDC receiving β-blocker therapy is associated with a distinct therapeutic molecular phenotype consisting of changes in expression of genes involved in AR signaling, contractile protein function, calcium handling, and metabolism. These changes are directionally opposite of previously described gene expression effects of chronic β 1 -AR stimulation, 5, 36 or transgenic myocardial overexpression, 6 which collectively constitute a β 1 -AR gene network. The biological effects of this gene network ultimately result in contractile dysfunction, hypertrophy, and adverse effects on myocardial metabolism, despite their positive inotropic acute effects. 8 The explanation for this biological dichotomy seems to be distinct differences in signaling with chronic gene expression changes mediated by protein kinase A-independent pathways 5 as opposed to protein kinase A-dependent acute effects. Changes in expression of these gene families may provide opportunities for directed pharmacological therapy, and further study is warranted to identify key regulatory nodes responsible for β-blocker therapy inhibiting the β 1 -AR gene network in some patients with IDC (responders) and not in others.
